Efficacy Safety and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

  • STATUS
    Recruiting
  • End date
    May 15, 2023
  • participants needed
    543
  • sponsor
    Alvotech Swiss AG
Updated on 23 June 2021
ustekinumab
plaque psoriasis

Summary

Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis

Description

AVT04 is a fully human immunoglobulin class G1 monoclonal antibody that specifically binds to the shared p40 protein subunit of IL-12 and IL-23 and therefore inhibits their activites

AVT04 is being developed to be a biosimilar with the European Union (EU)-licensed drug Stelara (hereafter referred to as Stelara) ustekinumab, Anatomical Therapeutic Chemical code: L04AC05) injection for subcutaneous (SC) and intravenous use. Stelara is an anti-IL-12 and anti-IL-23 monoclonal antibody approved for various indications. Indications approved in the EU11 and United States (US)12 include: PsO in adult and pediatric patients, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Indications approved in the People's Republic of China include PsO and Crohn's disease.13 Approval status may differ in other geographic regions.

This is a multicenter, double-blind, randomized, active control clinical study to compare the efficacy, safety, and immunogenicity of AVT04 versus Stelara in patients with moderate to severe chronic PsO.

The active period of Study AVT04-GL-301 comprises 2 stages:

  • Stage 1: Primary Efficacy Assessment (Day 1 to Week 15)
  • Stage 2: Long Term Efficacy and Safety Assessment (Week 16 to 52) Stage 1 On Day 1, after successfully completing Screening activities, eligible patients will be randomized into Groups 1 and 2, in a 1:2 ratio (AVT04:Stelara), and begin Stage 1.

Patient randomization will be stratified by presence or absence of previous biologic treatment, by region; ie, Europe or China, and by body weight category (80 kg vs >80 kg).

  • Group 1: Patients will receive an initial dose of AVT04 45 mg administered SC, followed by 45 mg 4 weeks later.
  • Group 2: Patients will receive an initial loading dose of Stelara, 45 mg administered SC, followed by 45 mg 4 weeks later.

Stage 2

At Week 16:

Patients who were initially randomized in Group 1 (AVT04) will continue to receive AVT04 45 mg SC every 12 weeks at Weeks 16, 28, and 40 (unless withdrawn from the study).

Patients who were initially randomized in Group 2 (Stelara) will be re-randomized into Groups 2A and 2B, in a 1:1 ratio:

  • Group 2A: Patients will begin receiving AVT04 45 mg SC every 12 weeks, at Weeks 16, 28, and 40 (unless withdrawn from the study).
  • Group 2B: Patients will continue to receive Stelara 45 mg SC every 12 weeks, at Weeks 16, 28, and 40 (unless withdrawn from the study).

At Week 28:

  • Non-responsive patients (PASI improvement <50% compared to BL) will be encouraged to continue in the study for safety analyses, per the Schedule of Assessments (SoA) (Table 7.1), but will not receive further study drug.
  • Responsive patients (PASI improvement 50% compared to BL) will continue in the study.

At Week 40: All patients who are still in the study (except Week 28 non-responsive patients) will receive the final study drug administration.

At Week 52 (EoS/ET): All patients will undergo final efficacy and safety assessment.

Details
Condition Psoriasis
Treatment Stelara, AVT04
Clinical Study IdentifierNCT04930042
SponsorAlvotech Swiss AG
Last Modified on23 June 2021

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note